Related references
Note: Only part of the references are listed.Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology
Paula Schmidt et al.
FRONTIERS IN IMMUNOLOGY (2021)
Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment
Sophie M. Poznanski et al.
CELL METABOLISM (2021)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Soo-Chin Lee et al.
CLINICAL CANCER RESEARCH (2020)
A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity
Joanne A. Hammill et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Ankit J. Kansagra et al.
BONE MARROW TRANSPLANTATION (2019)
What Defines NK Cell Functional Fate: Phenotype or Metabolism?
Sophie M. Poznanski et al.
FRONTIERS IN IMMUNOLOGY (2019)
Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
Jianguang Zhang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector
Aurelien B. L. Colamartino et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells
Tina Nham et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop
Viktoria Golumba-Nagy et al.
MOLECULAR THERAPY (2018)
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
Min Yu et al.
MOLECULAR THERAPY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
Folashade Otegbeye et al.
PLOS ONE (2018)
Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model
Sophie M. Poznanski et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Aleksei Titov et al.
CELL DEATH & DISEASE (2018)
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
Christopher W. Helsen et al.
NATURE COMMUNICATIONS (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Congcong Zhang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Veronika Kremer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
Stefan O. Ciurea et al.
BLOOD (2017)
Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours
Mira M. Shenouda et al.
BREAST CANCER RESEARCH (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial
Dean A. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
The Nucleotide-Binding Domain, Leucine-Rich Repeat Protein 3 Inflammasome/IL-1 Receptor I Axis Mediates Innate, but Not Adaptive, Immune Responses after Exposure to Particulate Matter under 10 mu m
Jeremy A. Hirota et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2015)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Human Tumor Antigens and Cancer Immunotherapy
Nathalie Vigneron
BIOMED RESEARCH INTERNATIONAL (2015)
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors
Joanne A. Hammill et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Effect of tumor cells and tumor microenvironment on NK-cell function
Massimo Vitale et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
Man Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Multifaceted roles of PGE2 in inflammation and cancer
Masako Nakanishi et al.
SEMINARS IN IMMUNOPATHOLOGY (2013)
Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy
Tolga Sutlu et al.
HUMAN GENE THERAPY (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1
Yuk Pheel Park et al.
BLOOD (2011)
Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4
Dawn Holt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling
Ludovic Martinet et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
Jaclyn A. Freudenberg et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2009)
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Anna Kruschinski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins
RD Ramirez et al.
CANCER RESEARCH (2004)
Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients
JC Lee et al.
JOURNAL OF IMMUNOLOGY (2004)
Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer
S Narai et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common γ-chain
PC Joshi et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
